Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Fallopian Tube Carcinoma”

99 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 99 results

Testing effectiveness (Phase 2)UnknownNCT00003064
What this trial is testing

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Herbert Irving Comprehensive Cancer Center 30
Large-scale testing (Phase 3)Study completedNCT00262990
What this trial is testing

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
Novartis Pharmaceuticals 829
Testing effectiveness (Phase 2)Study completedNCT00768144
What this trial is testing

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Dana-Farber Cancer Institute 36
Testing effectiveness (Phase 2)Study completedNCT00853307
What this trial is testing

MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Who this might be right for
Ovarian Carcinoma
Millennium Pharmaceuticals, Inc. 31
Testing effectiveness (Phase 2)WithdrawnNCT06393751
What this trial is testing

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Who this might be right for
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal Carcinoma+20 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)UnknownNCT02188550
What this trial is testing

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

Who this might be right for
Ovarian CancerEndometrial Cancer
Sinai Hospital of Baltimore 20
Testing effectiveness (Phase 2)Study completedNCT00466960
What this trial is testing

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Who this might be right for
Brenner TumorFallopian Tube CancerOvarian Clear Cell Cystadenocarcinoma+9 more
University of Washington 21
Testing effectiveness (Phase 2)UnknownNCT00003160
What this trial is testing

Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Theradex 100
Early research (Phase 1)Ended earlyNCT02948426
What this trial is testing

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
National Cancer Institute (NCI) 18
Early research (Phase 1)Study completedNCT00082823
What this trial is testing

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Cancer
Regeneron Pharmaceuticals 25
Testing effectiveness (Phase 2)Study completedNCT00189358
What this trial is testing

A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

Who this might be right for
Ovarian CancerCancer of the Fallopian TubePeritoneal Cancer
AGO Study Group
Testing effectiveness (Phase 2)Study completedNCT00091377
What this trial is testing

Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
MEI Pharma, Inc. 65
Early research (Phase 1)Study completedNCT00003358
What this trial is testing

Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Memorial Sloan Kettering Cancer Center 24
Large-scale testing (Phase 3)Study completedNCT00382811
What this trial is testing

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

Who this might be right for
Fallopian Tube CancerPeritoneal NeoplasmsOvarian Cancer
MEI Pharma, Inc. 142
Testing effectiveness (Phase 2)UnknownNCT00005025
What this trial is testing

Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
John Stoddard Cancer Center at Iowa Methodist Medical Center
Not applicableEnded earlyNCT00669422
What this trial is testing

ChemoFx® PRO - A Post-Market Data Collection Study

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer+5 more
Precision Therapeutics 2,756
Testing effectiveness (Phase 2)UnknownNCT01100372
What this trial is testing

Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Medical University Innsbruck 154
Testing effectiveness (Phase 2)Study completedNCT03026062
What this trial is testing

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
M.D. Anderson Cancer Center 100
Testing effectiveness (Phase 2)Looking for participantsNCT05271318
What this trial is testing

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

Who this might be right for
Platinum-refractory Ovarian CarcinomaPlatinum-resistant Ovarian CancerPlatinum-Resistant Fallopian Tube Carcinoma+6 more
TILT Biotherapeutics Ltd. 29
Early research (Phase 1)UnknownNCT04678102
What this trial is testing

Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)

Who this might be right for
Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CarcinomaPlatinum-Resistant Fallopian Tube Carcinoma+1 more
Seoul National University Hospital 36
Load More Results